-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
ChromaDex Announced Partnership With MyPharma2Go Corporation for Cross-Border Sales of Tru Niagen and Tru Niagen PRO Into Brazil
ChromaDex Announced Partnership With MyPharma2Go Corporation for Cross-Border Sales of Tru Niagen and Tru Niagen PRO Into Brazil
ChromaDex Corp. (NASDAQ:CDXC) today announced a partnership with MyPharma2Go to conduct cross-border sales of Tru Niagen and Tru Niagen PRO in Brazil, the first Latin American country to welcome the brand. Nicotinamide riboside or NR, the key ingredient in Tru Niagen, is the world's most efficient nicotinamide adenine dinucleotide (NAD+) precursor on the market, particularly over NMN (nicotinamide mononucleotide). MyPharma2Go, an American company focused on Brazil and Latin America, developed a cross-border e-commerce platform that allows patients to have direct access to international medicines and supplements, and monitors the international shipping process from origin to delivery. Tru Niagen is one of Amazon's (U.S.) top-selling brands in the Vitamin B3 category for boosting NAD+ levels and features ChromaDex's proprietary ingredient, Niagen (patented nicotinamide riboside or NR). The cross-border distribution strategy allows for Tru Niagen 300mg 30 count bottles, Tru Niagen 300mg 90 count bottles and Tru Niagen 300mg 30 count Stickpacks to be purchased by consumers looking to age healthier. Additionally, MyPharma2Go is working with Brazilian Health Care Professionals (HCPs) to distribute Tru Niagen PRO bottles, which feature 500mg of Niagen, the highest single capsule dose currently on the market, to patients across the country. Supplementation with Niagen is backed by 20 published and peer-reviewed clinical studies, many of which involve daily doses of 1000mg or more of Niagen. Niagen has achieved regulatory acceptance for use in supplements by the US FDA. Niagen has also been approved for use in food supplements by the European Commission, complementary medicines by the Therapeutic Goods Administration of Australia (TGA), and medical foods by the Food Standards Australia New Zealand (FSANZ). Tru Niagen has also been approved by Health Canada as a Natural Health Product. Additionally, ChromaDex continues to lead the industry in NAD+ research and recently announced that the ChromaDex External Research Program (CERPTM) reached over 250 material transfer agreements (MTAs) featuring Niagen and other proprietary ingredients
ChromaDex Corp. (NASDAQ:CDXC) today announced a partnership with MyPharma2Go to conduct cross-border sales of Tru Niagen and Tru Niagen PRO in Brazil, the first Latin American country to welcome the brand. Nicotinamide riboside or NR, the key ingredient in Tru Niagen, is the world's most efficient nicotinamide adenine dinucleotide (NAD+) precursor on the market, particularly over NMN (nicotinamide mononucleotide). MyPharma2Go, an American company focused on Brazil and Latin America, developed a cross-border e-commerce platform that allows patients to have direct access to international medicines and supplements, and monitors the international shipping process from origin to delivery. Tru Niagen is one of Amazon's (U.S.) top-selling brands in the Vitamin B3 category for boosting NAD+ levels and features ChromaDex's proprietary ingredient, Niagen (patented nicotinamide riboside or NR). The cross-border distribution strategy allows for Tru Niagen 300mg 30 count bottles, Tru Niagen 300mg 90 count bottles and Tru Niagen 300mg 30 count Stickpacks to be purchased by consumers looking to age healthier. Additionally, MyPharma2Go is working with Brazilian Health Care Professionals (HCPs) to distribute Tru Niagen PRO bottles, which feature 500mg of Niagen, the highest single capsule dose currently on the market, to patients across the country. Supplementation with Niagen is backed by 20 published and peer-reviewed clinical studies, many of which involve daily doses of 1000mg or more of Niagen. Niagen has achieved regulatory acceptance for use in supplements by the US FDA. Niagen has also been approved for use in food supplements by the European Commission, complementary medicines by the Therapeutic Goods Administration of Australia (TGA), and medical foods by the Food Standards Australia New Zealand (FSANZ). Tru Niagen has also been approved by Health Canada as a Natural Health Product. Additionally, ChromaDex continues to lead the industry in NAD+ research and recently announced that the ChromaDex External Research Program (CERPTM) reached over 250 material transfer agreements (MTAs) featuring Niagen and other proprietary ingredients
Chromadex 股份有限公司(NASDAQ:CDXC)今天宣布與 MyPharma2Go 建立合作夥伴關係,在巴西進行尼加根特魯尼亞根和 Tru 尼加根 PRO 的跨境銷售,這是第一個歡迎該品牌的拉丁美洲國家。煙酰胺核苷或 NR 是 Tru Nigen 的關鍵成分,是市場上世界上效率最高的煙酰胺腺嘌呤二核苷酸(NAD+)前體,特別是在 NMN(煙酰胺單核苷酸)之上。MyPharma2go 是一家專注於巴西和拉丁美洲的美國公司,開發了一個跨境電子商務平台,使患者可以直接獲得國際藥品和補充劑,並監控從產地到交付的國際運輸過程。Tru Nigen 是亞馬遜(美國)維生素 B3 類別中最暢銷的品牌之一,用於提高 NAD+ 水平,並採用 ChromaDeX 的專有成分尼亞根(專利煙酰胺核糖苷或 NR)。跨境分銷策略允許特魯尼亞根 300 毫克 30 計數瓶,特魯尼亞根 300 毫克 90 計數瓶和特魯尼亞根 300 毫克 30 計數 Stickpack 由希望年齡更健康的消費者購買。另外, MyPharma2Go 正在與巴西醫療保健專業人員 (HCPs) 分發特魯尼亞根 PRO 瓶, 其特點是尼亞根 500 毫克, 目前市場上最高的單膠囊劑量, 全國各地的患者.尼亞根的補充由 20 項已發表和同行評審的臨床研究支持,其中許多研究涉及每日劑量為 1000 毫克或更多的尼亞根。尼亞根已經取得了美國 FDA 在補充劑中使用的監管接受。尼亞根還獲得歐洲委員會批准用於食品補充劑,澳大利亞治療產品管理局(TGA)的補充藥物以及澳大利亞新西蘭食品標準局(FSANZ)批准用於醫療食品。Tru NiAGEN 也被加拿大衛生部批准為天然健康產品。此外,ChromaDeX 繼續在 NAD+ 研究領域領先業界,並最近宣布 Chromadex 外部研究計劃(CERPTM)達成了 250 多種材料轉讓協議(MTA),其中包括尼亞根和其他專有成分
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧